Newsfeeds - Spark Newswire

2 minute read

VYNE Therapeutics Divests Topical Minocycline Assets; Transaction Includes Cash Payments Of $25M And Potential Milestones Of Up To $450M

Today, 9:23 AM

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE's strategic plan; proceeds will be used to fund development of Company's

DERM

4 minute read

50 Biggest Movers From Friday

By Lisa Levin

Today, 9:23 AM

Gainers SigmaTron International, Inc. (NASDAQ: SGMA) jumped 84.7% to settle at $14.94 on Friday after the company reported Q2 EPS and sales results were higher year over year.

AGMH

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 9:23 AM

APDN

3 minute read

36 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 9:23 AM

Gainers

AGMH

2 minute read

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 9:23 AM

BFRI

2 minute read

18 Stocks Moving in Friday’s Pre-Market Session

By Lisa Levin

Today, 9:23 AM

Gainers Context Therapeutics Inc. (NASDAQ: CNTX) rose 48.6% to $9.30 in pre-market trading as the company announced data from ONA-XR in early breast cancer. The company said ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer.

1 minute read

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

Today, 9:23 AM

BPTH

1 minute read

HC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7

By Benzinga Newsdesk

Today, 9:23 AM

HC Wainwright & Co. analyst Joseph Pantginis assumes VYNE Therapeutics (NASDAQ:VYNE) with a Buy rating and announces Price Target of $7.

VYNE

2 minute read

Earnings

VYNE Therapeutics’s Return On Capital Employed Insights

By Benzinga Insights

Today, 9:23 AM

According to Benzinga Pro data, during Q3, VYNE Therapeutics (NASDAQ:VYNE) posted sales of $4.09 million. Earnings were up 5.35%, but VYNE Therapeutics still reported an overall loss of $17.78 million.

VYNE